Zenas BioPharma (ZBIO) Liabilities and Shareholders Equity (2023 - 2026)

Zenas BioPharma's Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $747.7 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 124.01% year-over-year to $747.7 million; the TTM figure through Mar 2026 stood at $1.7 billion (up 57.74% YoY), while the FY2025 annual figure was $383.6 million, up 3.7% from the prior year.
• Liabilities and Shareholders Equity was $747.7 million for Q1 2026 at Zenas BioPharma, up from $383.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $747.7 million in Q1 2026 to a low of $68.2 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $365.2 million across 4 years, with a median of $351.9 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity soared 442.63% in 2024, then fell 20.18% in 2025.
• A 4-year view of Liabilities and Shareholders Equity shows it stood at $68.2 million in 2023, then jumped by 442.63% to $370.0 million in 2024, then increased by 3.7% to $383.6 million in 2025, then jumped by 94.89% to $747.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $747.7 million (Q1 2026), $383.6 million (Q4 2025), and $322.0 million (Q3 2025), per Business Quant data.